ABL Bio introduces platform tech to speed up developing bispecific ADCs

As DLL3 heats up, early data for Zai Lab’s ADC sets up case for differentiation

Hengrui initiated the phase II clinical study of nectin-4 ADC monotherapy for advanced gynecological tumors

Adcentrx Therapeutics announces FDA clearance of Investigational New Drug Application for ADRX-0405, a potential first-in-class...

Gilead pulls Trodelvy’s approval in bladder cancer after trial flop, FDA discussions